STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

United Therapeutics insider files Form 144 to sell 112,500 shares

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

United Therapeutics insider filed a Form 144 to sell 112,500 shares of common stock on 09/02/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing lists an aggregate market value of $34,285,500.00 and reports 45,226,262 shares outstanding. The shares were acquired the same day, 09/02/2025, by exercise of stock options and paid in cash. No securities were reported sold by the person in the prior three months, and the filer represents they have no undisclosed material adverse information.

Positive

  • Filer provided required Rule 144 disclosure including broker, share count, acquisition method, and representation regarding material information
  • No sales reported in the prior three months for the selling person, indicating this is a single disclosed transaction

Negative

  • None.

Insights

TL;DR: Insider exercised options and intends to sell 112,500 shares worth $34.3M; routine disclosure with limited standalone market impact.

The filing shows a single transaction: exercise of stock options and proposed sale of 112,500 common shares on 09/02/2025 through Morgan Stanley Smith Barney LLC at an aggregate market value of $34,285,500. The filing reports 45,226,262 shares outstanding, providing context for scale. There are no reported sales by the person in the prior three months. This is a standard Rule 144 notice documenting a proposed sale rather than financial results or new corporate actions. From the filing alone, there is no additional operational or financial information disclosed.

TL;DR: The disclosure complies with Rule 144 reporting for an insider option exercise and sale; it includes the required representations and signatures.

The Form 144 contains the necessary elements: issuer and broker identification, class of securities, number of shares (112,500), acquisition method (exercise of stock options on 09/02/2025), payment in cash, and the filer’s representation about material non-public information. The filing notes no aggregated sales in the past three months. Based solely on the document, this is a routine compliance filing without governance changes or additional disclosures.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What is being reported in the UTHR Form 144?

The filing reports a proposed sale of 112,500 common shares acquired by exercise of stock options on 09/02/2025, to be sold via Morgan Stanley Smith Barney LLC on NASDAQ.

How much is the aggregate market value of the shares in the filing?

The aggregate market value is reported as $34,285,500.00.

When were the shares acquired and how were they paid for?

The shares were acquired on 09/02/2025 through the exercise of stock options and payment was made in cash on the same date.

Does the filing show other recent sales by the same person?

No. The section for securities sold during the past three months states: Nothing to Report.

Which broker is handling the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
United Therapeutics Corp.

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Latest SEC Filings

UTHR Stock Data

21.03B
42.14M
1.77%
99.51%
5.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SILVER SPRING